Patents Assigned to ONXEO
  • Oral formulations of belinostat
    Patent number: 11266614
    Abstract: The present application concerns new formulations of belinostat suitable for oral administration, their process of preparation, the pharmaceutical compositions comprising said formulations and their uses thereof.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: March 8, 2022
    Assignee: ONXEO
    Inventors: Perrine Pivette, Caroline Lemarchand, Ian Yates, Corey Bloom
  • Use of a combination of Dbait molecule and PARP inhibitors to treat cancer
    Patent number: 11162095
    Abstract: The present invention relates to the combination of a PARP inhibitor with a Dbait molecule for treating cancer.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: November 2, 2021
    Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ONXEO, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS-SUD 11
    Inventors: Marie Dutreix, Wael Jdey
  • Treatment of cancer by systemic administration of Dbait molecules
    Patent number: 10821128
    Abstract: The present invention relates to the use of a DBait molecules by systemic routes without any combination with an endosomolytic agent.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: November 3, 2020
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Marie Dutreix, Nathalie Berthault
  • Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
    Patent number: 10765758
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: September 8, 2020
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • Use of a combination of Dbait molecule and PARP inhibitors to treat cancer
    Patent number: 10563197
    Abstract: The present invention relates to the combination of a PARP inhibitor with a Dbait molecule for treating cancer.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: February 18, 2020
    Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ONXEO, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS-SUD 11
    Inventors: Marie Dutreix, Wael Jdey
  • Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
    Patent number: 10363317
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: July 30, 2019
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
    Patent number: 9687557
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: June 27, 2017
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz